Sana Biotechnology, Inc. Cash Flow Statement
SANA / Health Care|6 years of annual SEC 10-K data (FY2019-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Sana Biotechnology, Inc. used $223M in operating cash flow and negative free cash flow of $257M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Net Income | -$266.8M | -$283.3M | -$269.5M | -$355.9M | -$285.3M | -$130.8M |
| Depreciation & Amortization | $17.4M | $24.6M | $15.6M | $11.1M | $5.9M | $1.8M |
| Operating Cash Flow | -$223.2M | -$253.6M | -$290.1M | -$251.1M | -$138.0M | -$85.5M |
| Capital Expenditures | $33.4M | $20.0M | $20.9M | $29.9M | $23.9M | $26.1M |
| Free Cash Flow | -$256.6M | -$273.6M | -$310.9M | -$280.9M | -$161.9M | -$111.6M |